21.11.2023 - Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a . Seite 1
By Sabela Ojea Shares of Pulse Biosciences jumped on Tuesday after the company said that it submitted a Food and Drug Administration premarket application for its CellFX nsPFA percutaneous.
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator: Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.